

2025 OFFICE MANAGER SYMPOSIUM

MARIA CASTAÑO, PharmD

SENIOR DIRECTOR – QUALITY & PHARMACY PROGRAMS



1

TODAY'S AGENDA

1. Welcome
2. Defining Value Based Care
3. MHN Progress Report
4. Tips & Best Practices
5. Summary & Conclusion




2

What is Value-Based Care?

Value-based care (VBC) is a system designed to focus on quality of care, provider performance, and patient experience

- **Value** = Prioritizes the results that matter to the patient; does **not** mean cheaper care
- **Integrated Care Delivery** = PCP and other providers work together to manage a **whole person's health**; this includes access to transportation, healthy food, and relationship with family



What is Value-Based Care? (continued)

- The National Academy of Medicine described a framework for quality that can be used to hold providers accountable in VBC models. These components include:
 - **Effectiveness** – Care is based on evidence
 - **Efficiency** – Only necessary resources are utilized
 - **Equity** – Care does not vary in quality based on race, income, etc.
 - **Patient centeredness** – Each patient's needs and values are respected
 - **Safety** – Treatment does not cause harm
 - **Timeliness** – Treatment is available without long delays

Why Value-Based Care?

- VBC ties the amount earned by health care providers to the results of the care they deliver to patients
- The idea is to correct the misaligned incentives of the U.S. fee-for-service system
- Despite spending more on health care than any other developed nation in the world, the U.S. does not have the best results



5

How does the Provider benefit?

- By participating in a clinically-integrated network, providers can more easily manage their patients across the health care continuum
PCP ↔ Specialist ↔ Pharmacy ↔ Disease Management
- Financial incentives are aligned among all stakeholders, including health plans; this results in generation of shared savings
- Providers are rewarded for providing high-quality, efficient care with improved outcomes



6

How does the Patient benefit?

- Person's physical, mental, behavioral, and social needs are addressed
- Person is treated as an individual rather than an organ system or a specific disease process
- Access to health education resources, including disease management and prevention programs
- Result: Healthier patients **without** increased costs



7

MHN is Claims-Based

- Data on reports **is lagged** due to the time it takes for claims to be submitted to the payer, adjudicated, paid (or not), and then sent to MHN.
- MHN Attribution happens one of three (3) ways:
 - 1) A claim is received from a primary care provider (PCP)
 - 2) Patient selects a doctor in the network to be their PCP
 - 3) Payer assigns the patient to a provider




8

MHN is Claims-Based (continued)

Appropriate coding and documentation results in:

- ▶ Fewer rejected claims
- ▶ Appropriate reimbursement for rendered services
- ▶ Care gap closure



9

2025 MHN Reports



10

MHN Reports

- **Care Gap Reports:** provided monthly beginning in June
- **Progress Reports:** provided quarterly beginning in the second quarter (Q2 through Q4)
- Both reports are from DoNotReplyMHN@mhs.net
 - **Best Practice:** *Download and save attached reports immediately upon receipt*
- Reports are claims-based, so the data are lagged by as much as **three months**



11

MHN Care Gap Reports

- A care gap indicates the patient is due for some type of follow-up, such as:
 - Wellness visit
 - Preventive screening (colorectal cancer, breast cancer, etc.)
 - Disease-related follow-up (Hemoglobin A1c, eye exam, etc.)
- **Please note the date on the report** – There is a delay/lag in claims-based reports



12

MHN Care Gap Report



Provider: [REDACTED]
[REDACTED] FAMILY PRACTICE

Contract Year 2024
Care Gap Provider Feedback Report as of 10/31/2024

Note the date on the report

Member ID / Name	DOB / Age / Gender	MRN	Measure	Primary Care Physician
[REDACTED]	[REDACTED] 53 M	[REDACTED]	CBP-Controlling High Blood Pressure	
[REDACTED]	[REDACTED] 46 F	[REDACTED]	COL-Colorectal Cancer Screening	
[REDACTED]	[REDACTED] 21 M	[REDACTED]	WCV-Well Care Visit age 3-21	
[REDACTED]	[REDACTED] 51 F	[REDACTED]	COL-Colorectal Cancer Screening	
[REDACTED]	[REDACTED] 65 F	[REDACTED]	CBP-Controlling High Blood Pressure	
[REDACTED]	[REDACTED] 24 F	[REDACTED]	CHL-Chlamydia Screening in Women	
[REDACTED]	[REDACTED] 55 F	[REDACTED]	BCS - Mammogram	
[REDACTED]	[REDACTED] 55 F	[REDACTED]	COL-Colorectal Cancer Screening	
[REDACTED]	[REDACTED] 50 F	[REDACTED]	COL-Colorectal Cancer Screening	
[REDACTED]	[REDACTED] 57 M	[REDACTED]	COL-Colorectal Cancer Screening	
[REDACTED]	[REDACTED] 62 F	[REDACTED]	CBP-Controlling High Blood Pressure	
[REDACTED]	[REDACTED] 62 F	[REDACTED]	COL-Colorectal Cancer Screening	

Reports are distributed at the end of the month from June through November of the performance year

HEDIS Measure Legend:

BCS = Breast Cancer Screening
CDC = Comprehensive Diabetes Care
W30 = Well Child Exam

CPB = Controlling High Blood Pressure
CHL = Chlamydia Screening
WCV = Child & Adolescent Well Exam

CCS = Cervical Cancer Screening
COL = Colorectal Cancer Screening

10/31/2024

This report contains Protected Health Information. As you and your office are Covered Entities, please ensure compliance with HIPAA Privacy and Security Rules.



13

MHN Progress Report (page 1)



Provider Progress Report

Interim Score: 47.1%
Total CI Points: 8 of 17

NAME: [REDACTED]
SPECIALTY: FAMILY PRACTICE
NPI: [REDACTED]
DATES EVALUATED: January - September 2024
REPORT GENERATED: Monday, November 25, 2024

Note the date on the report

Citizenship Domain

Measure Name	Points Earned	Points Available
Clinical Integration Education: Program Update	1	1
MHN Second Education Topic	1	1
Physician Survey	0	0
Office Manager Symposium	1	1
After Hours Access (BONUS)	1	0



Efficiency Domain

Measure Name	Goal	Numerator	Denominator	Result	Points Earned	Points Available
Generic Medication Usage	> 90%	1015.00	1156.00	88%	0	2
ED visits/1000 - (# ED visits X 12,000) / Member Months	< 250	558.00	21188.00	316.0	0	1
Average Length of Stay	<			No Data	0	0



Readmission Measures

Measure Name	Goal	MHS Rate	Cohort Rate	MHS/Cohort Rate	Points Earned	Points Available
Adult Readmissions Ratio 30-Day All Cause (Observed / Expected)	< 1	10.69	10.16	1.05	0	1
Adult Readmissions Ratio Heart Failure (Observed / Expected)	< 1	20.21	19.31	1.05	0	1



Reports are distributed quarterly from Q2 through Q4 of the performance year

Additional dates in the report footer

Citizenship metrics results reported as of Nov 12th, 2024.
Efficiency metrics reported as of Jan-Sept 2024 except Inpatient metrics based on rolling 12 months of data.
Readmission measures based on rolling 12 months of data.
Quality metrics reported Jan-Sept 2024 except OB/GYN metrics based on rolling 12 months of data.



14

MHN Progress Report (page 2)




Provider Progress Report

Interim Score: 47.1%
Total CI Points: 8 of 17

NAME: FAMILY PRACTICE
SPECIALTY:
NPI:
DATES EVALUATED: January – September 2024
REPORT GENERATED: Monday, November 25, 2024

Quality Domain

Population Health Wellness Initiative



Shows point assignment

Diabetes Care

* Members who had a HbA1c within Measurement Year
Points: 1 of 1



* HbA1c Control (less than 8.0)
Points: 0 of 1



* Eye Exam
Points: 0 of 1



Cardiovascular Disease

* Controlling High Blood Pressure
Points: 0 of 1



OB/GYN

Cesarean Section Rate
Not Assigned

Episiotomy Rate
Not Assigned

Red = NOT meeting measure goal
Green = meeting measure goal



15

MHN Progress Report Measures 2025

Progress Report measures comprise three (3) domains/sections:

- 1) Citizenship – **Applies to all MHN providers**
 - 2) Quality
 - 3) Efficiency
- Assignment is based on providers' specialty*



16

Citizenship Measures 2025

There are three measures worth 1 point each plus one bonus point for eligible practices

1. Clinical Integration Education (CI Update)
2. MHN Second Education Topic
3. Office Manager Symposium ★
4. Extended Hours (***bonus for eligible providers***)



17

Extended Hours Access (Bonus)

- ✓ Only ***office-based*** providers are eligible for this bonus point.
- ✓ Must provide completed ***After Hours Access Attestation*** form
 - *Appointments must be available for BOTH new and existing patients during the times specified on the form.*
 - MHN personnel may contact your office to request an appointment on behalf of a patient during the times specified on the form.

Memorial Health Network
After-Hours Access Attestation

After-hours access is defined as either one of the following:
 (a) Any office hours on Saturday or Sunday (anytime) ...or...
 (b) Any additional office hour(s) on weekdays (Monday through Friday) before 8 AM or after 6 PM.

I, _____ attest that our practice _____ has after-hour access as stated in the table below.

Day of Week	Sunday	Monday	Tuesday	Wednesday	Thursday	Friday	Saturday
Office Hours							

☐ We are only available on-call in an emergency.

☐ Our practice does not have any after-hours options available for our patients.

Signature _____ Print Name _____
 Title _____ Date _____

Please return **completed and signed** form to Macastano@mhs.net



18

2025 QUALITY MEASURES



19

HEDIS Quality Measures 2025

Changes for 2025:

1. Retired *Annual Hemoglobin A1c* test measure
2. New Measure: Use of Opioids at High Dosage

Total # HEDIS Quality Measures:	13
Total # Efficiency Measures:	3
Readmission Measures (Adult):	2
Readmission Measures (Peds):	1



20

NEW Use of Opioids at High Dosage (HDO)

Measures the percentage of members 18 years of age and older who received prescription opioids at a high dosage, defined as morphine milligram equivalent (MME) dose ≥ 90 , for ≥ 15 days during the measurement year.

- Data from pharmacy claims
- Attributed to *all providers*
- Will not be scored in 2025
- Exclusions: Cancer, sickle cell, hospice, palliative care

Opioid	MME Conversion
Codeine sulfate	0.15
Fentanyl patch (mcg/hr)	2.4
Hydrocodone	1
Hydromorphone	4
Morphine	1
Oxycodone	1.5
Tramadol	0.2



21

How is MME Calculated?

Example: Patient prescribed Percocet (oxycodone) 5 mg/325 mg #120 tablets per 30 days supply. What is the MME equivalent for this Rx?

1. Calculate the total milligrams of the opioid taken each day

$$5 \text{ mg/tablet} \times 4 \text{ tablets/day} = 20 \text{ mg oxycodone}$$

2. Multiply by the MME conversion factor

$$20 \text{ mg} \times 1.5 = 30 \text{ MMEs}$$

Result: Rx does not meet the 90 MME threshold

Opioid	MME Conversion
Codeine sulfate	0.15
Fentanyl patch (mcg/hr)	2.4
Hydrocodone	1
Hydromorphone	4
Morphine	1
Oxycodone	1.5
Tramadol	0.2



22

Well-Child Visits in the First 30 Months of Life (w30)

Two (2) age stratifications:

- 1) Children who turn 15 months during measurement year: Must have had **6 or more** well visits during this timeframe
- 2) Children who turn 30 months during measurement year: Must have had **2 or more** well visits between 15 -30 months of age

Description	CPT	ICD-10-CM
Infant (Younger than 1 year)	99381 New patient 99391 Established	• Z00.110 Health supervision for newborn under 8 days old • Z00.111 Health supervision for newborn up to 28 days old
Early Childhood (Ages 1 to 4 years)	99382 New Patient 99392 Established	• Z00.121 Routine child health exam with abnormal findings • Z00.129 Routine child health exam without abnormal findings

**** As of 1/1/2025: Telehealth visits no longer count towards measure compliance ****



23

Child & Adolescent Well Care Visits Ages 3-21 (wcv)

Measures the percentage of members 3-21 years of age who had **at least one** comprehensive well-care visit with a PCP or OB/GYN **during the measurement year**

Description	CPT	ICD-10-CM
Early childhood (Ages 1 to 4 years)	99382 New patient 99392 Established	• Z00.121 Routine child health exam with abnormal findings • Z00.129 Routine child health exam without abnormal findings
Late childhood (Ages 5 to 11 years)	99383 New patient 99393 Established	
Adolescent (Ages 12 to 17 years)	99384 New patient 99394 Established	
Adult (Ages 18 years and up)	99385 New patient 99395 Established	• Z00.00 General adult medical exam without abnormal findings • Z00.01 General adult medical exam with abnormal findings

**** As of 1/1/2025: Telehealth visits no longer count towards measure compliance ****



24

Breast Cancer Screening Ages 50-74 (BCS)

Measures the percentage of women 50-74 years of age who have had at least one mammogram in the **previous 27 months** (10/2023 - 12/2025)

- ▶ Women who have undergone a bilateral mastectomy (Z90.13) at any time during their history are **excluded** from this measure

Description	CPT	ICD-10-CM	HCPCS
Mammography bilateral	77065 - unilateral 77066 - diagnostic 77067 - screening	Z12.31 – Encounter for screening mammogram for malignant neoplasm of breast	G0206 – unilateral G0204 – diagnostic G0202 – screening G9899 – screening results have been documented & reviewed
Exclusion: Bilateral mastectomy		Z90.13 – Hx bilateral mastectomy	



25

Cervical Cancer Screening - Ages 21-64 (CCS)

Description	CPT	ICD-10-CM	HCPCS
Women 21–64 years of age: Cervical cytology performed every 3 years (2023-2025)	88141-88143, 88147-88148, 88150, 88152, 88153, 88164-88167, 88174-88175		G0123, G0124, G0141, G0143, G0144, G0145, G0147, G0148, P3000, P3001, Q0091
Women 30–64 years of age: Cervical cytology/ HPV co-testing performed every 5 years (2021-2025)	87624, 87625		G0476 (must be documented in addition to PAP test as indicated above)
Exclusion: "Total", "Complete" or "Radical" hysterectomy; Hysterectomy with no residual cervix	57530, 57531, 57540, 57545, 57550, 57555, 57556, 58150, 58152, 58200, 58210, 58240, 58260, 58262, 58263, 58267, 58270, 58275, 58280, 58285, 58290-58294, 58548, 58550, 58552-58554, 58570-58573, 58575, 58951, 58953, 58954, 59856, 59135	Q51.5, Z90.710, Z90.712	



26

Chlamydia Screening (CHL)

Measures the percentage of individuals **16 – 24** years of age who were identified as sexually active via medical claims or pharmacy data (oral contraceptives) and who had at least one test for chlamydia **during the measurement year (2025)**

Chlamydia screening can be done via urine test or vaginal swab

Exclusion: Members who were assigned male at birth

Coding: Measure compliance is assessed by CPT code submission

Chlamydia Test CPT Codes

87110, 87270, 87320, 87490-87492, 87810



27

Colorectal Cancer Screening - Ages 46-75 (COL)

Measures the percentage of members 46-75 years of age who had appropriate screening for colorectal cancer as shown below:

Description	CPT	HCPCS
Colonoscopy Every 10 years (2016 – 2025)	44388-44394, 44397, 44401-44408, 45355, 45378-45393, 45398	G0105, G0121
Flexible sigmoidoscopy Every 5 years (2021-2025)	45330-45335, 45337, 45338, 45340-45342, 45346, 45347, 45349, 45350	G0104
CT Colonography Every 5 years (2021-2025)	74261-74263	
Cologuard or FIT-DNA (stool DNA test) Every 3 years (2023-2025)	81528	
Fecal Occult Blood Test (FOBT) Yearly (2025)	82270 82274	G0328



28

Stool Tests for Colorectal Cancer Screening

There are two (2) types of stool tests:

1. Fecal occult blood test

- FOBT, Guaiac test – checks for presence of hemoglobin
- FIT test – uses antibodies to detect blood in stool
- Must be done *yearly*

2. Fecal occult blood + DNA test

- Cologuard
- FIT-DNA/ Stool DNA – Detects blood *plus* altered DNA in stool
- Can be done *every 3 years*



29

Document Clearly & Appropriately

The following are NOT acceptable for closing care gaps:

- Tests performed in an office setting *or* from any specimen collected during a digital rectal exam
- CT scan of abdomen or pelvis

Avoid abbreviations whenever possible

- Example "COL" or "COL 2022"
Colostomy? Colectomy? Colonoscopy? Cologuard?



30

Colorectal Cancer Screening Exclusions (COL)

Required Exclusion	ICD-10-CM	CPT	HCPCS
Enrollment in palliative care	Z51.5		
Utilization of hospice services			Q5001 – Q5010
Frailty or advanced illness	R54		G2099
Living in Long Term Care/ ALF		99341 – 99345 99347 – 99350	
History of colorectal cancer diagnosis	C18.0 – C18.9, C19, C20, C21.2, C21.8, C78.5, Z85.038, Z85.048		
History of total colectomy		44150 – 44153, 44155 – 44158, 44210 – 44212	



31

Diabetes Care: Hemoglobin A1c Control <8%

Measures the percentage of members 18-75 years of age with diabetes (type 1 and type 2) who had Hemoglobin A1c (HbA1c) testing within the measurement year and the value returned as **below 8.0%**

- Measure performance is recorded via *CPT II coding*

CPT II Code	Hemoglobin A1c (HbA1c) Level
3044F	Less than 7.00
3051F	7.00 – 7.99
3052F	8.00 – 9.00
3046F	Greater than 9.00

The most recent test result from measurement year (2025) is the one that counts towards measure compliance




32

Diabetes Care: Eye Exam (CDC)

Measures the percentage of members 18-75 years of age with diabetes (type 1 and type 2) who had a comprehensive eye exam to screen/monitor for diabetic retinal disease, including:

- A retinal or dilated eye exam in the measurement year (2025) ****OR****
- A negative retinal or dilated eye exam (negative for retinopathy) in the year prior to the measurement year (2024)



***Exam must be interpreted
by an eye care professional
(optometrist or
ophthalmologist)***



33

Diabetes Care: Eye Exam – Best Practices

Educate patient on the risks of Diabetic Eye Disease and encourage scheduling an **annual eye exam**

- Obtain eye exam reports. Document eye care provider name and contact information in chart
- Documentation can be in the form of a note or letter prepared by the eye care professional and must include the date of service, the test and result, and the provider's credentials
 - Example of appropriate documentation: *Diabetic retinal or dilated eye exam with Donald Blake, OD, June 2024, no retinopathy*
- Prior year exam results must indicate retinopathy was **NOT PRESENT**



34

Diabetes Care: Eye Exam – CPT Coding

CPT Codes document that the exam was performed (but not the result)

Description of Exam*	CPT Code
Imaging of retina for detection or monitoring of disease With remote clinical staff review and report	92227
Imaging of retina for detection or monitoring of disease With remote physician or other qualified health care professional interpretation and report	92228
Imaging of retina for detection or monitoring of disease Point of care automated analysis and report (AI Interpretation)	92229

***Date of service must be provided**

If previous year's exam is being used, then *must include CPT II code* to communicate that exam was negative for retinopathy!



35

Diabetes Care: Eye Exam – CPT II Coding

CPT II Codes document the result of the Diabetic Eye exam.

Description	CPT II Code	CPT II Code Description
Current year (2025) Dilated retinal screening with evidence of retinopathy	2022F 2024F 2026F	- Dilated retinal exam w/interpretation by eye care professional documented & reviewed - 7 standard field stereoscopic photos w/interpretation by eye care professional documented & reviewed - Eye imaging validated to match dx from 7 standard field stereoscopic photos results documented & reviewed
Current year (2025) Dilated retinal screening without evidence of retinopathy	2023F 2025F 2033F	- Dilated retinal exam w/interpretation by eye care professional documented & reviewed - 7 standard field stereoscopic photos w/interpretation by eye care professional documented & reviewed - Eye imaging validated to match dx from 7 standard field stereoscopic photos results documented & reviewed
Prior year (2024) Dilated retinal screening without evidence of retinopathy	3072F	- Low risk for retinopathy (no evidence of retinopathy in the prior year)



36

Hypertension – Controlling High Blood Pressure (CBP)

Measures the percentage of patients ages 18-85 years who have a diagnosis of hypertension and whose **most recent BP** during the measurement year is **BELOW 140/90** mmHg.

The BP reading **cannot** be used if:

- ▶ BP was taken during an acute inpatient stay or ED visit
- ▶ BP was taken on the same day as diagnostic test requiring change in diet or medication (except fasting blood test)
- ▶ BP was taken by patient using a *non-digital* device



37

Blood Pressure Measurement – Best Practices

- Offer restroom facilities prior to taking BP
- Allow 5-10 minutes to sit and relax prior to any BP reading
- Provide a comfortable chair with back support
- Ensure there is an arm rest at heart level for taking BP reading
- Check to see if feet are flat on the floor with legs uncrossed
- Do not speak or ask questions during the time the reading is taken



38

Measuring Accurate Blood Pressure (continued)

- Use the correctly sized cuff based on mid-arm circumference

Mid-Arm Circumference	Cuff Size
Less than 10.2 inches (26 cm)	Small Adult
10.2 – 13.4 inches (26 – 34 cm)	Regular Adult
13.4 – 17.3 inches (34 – 44 cm)	Large Adult
More than 17.3 inches (44 cm)	Extra Large Adult



- Too small cuff size → Falsely elevated BP
- Too large cuff size → Falsely decreased BP

Hypertension – Controlling High Blood Pressure (CBP)

Measure performance is tracked exclusively via CPT II coding

CPT II Code	SYSTOLIC BP Value
3074F	< 130 mm Hg
3075F	130 – 139 mm Hg
3077F	≥ 140 mm Hg
CPT II Code	DIASTOLIC BP Value
3078F	< 80 mm Hg
3079F	80 – 89 mm Hg
3080F	≥ 90 mm Hg


Quality Measures for Obstetrics: Cesarean Section & Episiotomy Rates

- The Leapfrog Group reports rates across the U.S. annually
 - This report represents 80% of the inpatient beds in the U.S
 - **Good news:** Episiotomy rates continue to decline
 - **Not-so-good news:** C-section rates are (still) relatively high
- Rates reported on MHN Progress Report reflect deliveries across **MHS facilities only**



41

Cesarean Section Rate



NTSV = Nulliparous, Term, Singleton, Vertex

- C-section rates are *not* improving nationally
- Rates of primary C-sections have been steadily increasing at MHS facilities between 2022-2024
 - 2022 Performance = 23%
 - 2023 Performance = 25%
 - 2024 Performance = 26%


2025 Network Goal: ≤24%

Source: The Leapfrog Group, State of Maternity Care in U.S. Hospitals. Retrieved June 16, 2025, from www.leapfrog.org



42

Episiotomy Rate



- Episiotomy rates have declined 73% nationally since 2012
- Rates of episiotomies have been steadily *decreasing* at MHS facilities between 2022-2024
 - 2022 Performance = 4%
 - 2023 Performance = 3%
 - 2024 Performance = 1%

2025 Network Goal: $\leq 7\%$

Source: The Leapfrog Group, State of Maternity Care in U.S. Hospitals. Retrieved June 16, 2025, from www.leapfrog.org



43

2025 EFFICIENCY METRICS



44

Generic Prescribing Rate

Measures the ratio of generic prescriptions divided by the total prescriptions (brand and generic) authorized for MHN-attributed members during the measurement year (2025).

Inpatient orders are not counted towards this measure

Goal: Varies by specialty and is based upon historical (prior year) performance

Exclusions: Branded Levothyroxine products and vaccines/toxoids

Threshold: 25 total outpatient prescriptions



45

Generic Prescribing Rate (continued)

Tips for improving your generic prescribing rate:

1. Prescribe generic medications whenever possible (first-line therapy)
2. Avoid routinely documenting "medically necessary" on prescriptions
3. Prescribe a 3-month supply for *eligible* maintenance (not specialty) medications
4. Request your pharmacy report to see whether you have opportunities for generic prescribing
5. Educate your patients about the benefits of generic medication



46

Memorial
Health Network

		Provider: Marcus Welby, MD Specialty: Internal Medicine Prescribing Date: 08/20/2018 90% CPE Clinical Prescribing Rule ID: 1953				
Refill and Dose		Member Name	Rx Refill Date	Plan	Paid Days	Quantity
ATRIALIN DISC 250MG TO MCG/DQY POWDER FOR INHALATION		PATIENT NAME	6/23/2019	\$500	00	3
ATRIALIN DISC 250MG TO MCG/DQY POWDER FOR INHALATION		PATIENT NAME	6/23/2019	\$500	00	3
BYSTOLIN 2 MGS TABLET		PATIENT NAME	7/26/2019	\$500	00	90
BYSTOLIN 2 MGS TABLET		PATIENT NAME	5/9/2019	\$500	00	90
BYSTOLIN 2 MGS TABLET		PATIENT NAME	5/9/2019	\$500	00	90
BYSTOLIN 2 MGS TABLET		PATIENT NAME	1/17/2019	\$0	00	90
BYSTOLIN 2 MGS TABLET		PATIENT NAME	4/24/2019	\$0	00	90
BYSTOLIN 2 MGS TABLET		PATIENT NAME	05/01/2019	\$0	00	90
Brand Rx Name		Member Name	Rx Refill Date	Plan	Paid Days	Quantity
CHANTIX		PATIENT NAME	5/24/2019	\$180	00	30
NOVOCALIN 100 MG/INHAL ASPART 300 UNIT/LINAL SURCUTANICUS		PATIENT NAME	7/13/2019	\$180	00	56
NOVOCALIN 100 MG/INHAL ASPART 300 UNIT/LINAL SURCUTANICUS		PATIENT NAME	5/14/2019	\$180	00	56
NOVOCALIN 100 MG/INHAL ASPART 300 UNIT/LINAL SURCUTANICUS		PATIENT NAME	2/24/2019	\$180	00	28
PERIARMO 160 MGS 1 MGS TABLET		PATIENT NAME	2/24/2019	\$180	00	28
PERIARMO 160 MGS 1 MGS TABLET		PATIENT NAME	2/24/2019	\$180	00	28
PERIARMO 160 MGS 1 MGS TABLET		PATIENT NAME	2/24/2019	\$180	00	28
PERIARMO 160 MGS 1 MGS TABLET		PATIENT NAME	6/26/2019	\$180	00	28
PERIARMO 160 MGS 1 MGS TABLET		PATIENT NAME	7/26/2019	\$180	00	28
PERIARMO 160 MGS 1 MGS TABLET		PATIENT NAME	5/14/2019	\$180	00	28
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	5/23/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	5/23/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512	00	60
TRUQUITY 1.5 MGS 1 MGS SURCUTANICUS PEN INJECTOR		PATIENT NAME	2/11/2019	\$512		

- 
- Memorial**
Health Network

ED Visits per Thousand

For group practices: The practice rate will be used, NOT individual physician

A collection of first aid supplies is displayed on a light blue background. From left to right, the items are: a red first aid kit with a white cross, a white thermometer, a glass syringe with a red plunger, a white plastic bottle of medicine, a white spray bottle with a red trigger, a yellow adhesive bandage, and several white round pills.



Memorial
Health Network

24


Average Length of Stay

Reports the arithmetic average length of stay for all cases attributed to a provider over a rolling 12-month period

Value indicates the provider's average length of stay for cases within the *Memorial Healthcare System* hospitals

Attributed only to the "responsible" physician on the case, not all providers in the practice

Threshold: **10** cases



49

30-Day All-Cause Readmission Ratio: Adult & Pediatrics

Adult and pediatric rates are reported separately

Applies to patients attributed to MHN providers regardless of payer

Observed Score: Aggregate measure of network readmissions (*not* individual physician performance)

Expected Score: Measures the Crimson "Florida Hospitals" cohort readmissions

Goal: $\frac{\text{Observed score (MHN rate)}}{\text{Expected score (Cohort rate)}} \leq 1.0$



50

30-Day Heart Failure Readmission Ratio

Adult patients with Heart Failure DRG attributed to MHN providers, regardless of payer

Observed Score: Aggregate measure of network readmissions for Heart Failure DRG (*not* individual physician performance)

Expected Score: Measures the Crimson "Florida Hospitals" cohort readmissions for heart failure DRG

Goal: $\frac{\text{Observed score (MHN rate)}}{\text{Expected score (Cohort rate)}} \leq 1.0$



51

TOP 5 REASONS FOR REDUCED HEDIS MEASURE PERFORMANCE

1. Patient did not follow-through on ordered service/procedure
 - Diabetic (dilated) eye exam
 - Other screening tests (labs, mammograms, etc.)
2. Service *was* provided, but claim contains incorrect or missing CPT and/or CPTII codes
3. Service was provided outside of the required time frame
4. Measure exclusion(s) were not coded properly
5. Claims were not submitted in a timely manner



52

TIPS AND BEST PRACTICES



53

Tips and Best Practices



Use your attribution list to contact patients due/overdue for an exam or those who are new to your practice



Most measure performance can be recorded via claims when complete and accurate coding is used



Take advantage of the information presented here and the MHN Fact Sheet to help your practice understand HEDIS measures



Contact your patients to remind of appointments and preventative screenings via Care Gap & Attribution Reports



54

Tips and Best Practices (continued)



Most Electronic Health Records (EHRs) have functionality to create alerts for overdue screenings *and* share data with other providers

Be sure to have these prompts turned **on** or check with your software vendor to have these added to your EHR



Consider extending your office hours into the evening, early morning, or weekend to accommodate your patients' work schedules

Benefits include decreased ED visits, greater patient engagement, and practice growth



55

OPTIMIZE YOUR OFFICE WORKFLOW



Front Desk

Verify patient information, check for overdue AWV or WCE and notify MA/Nurse



MA or Nurse

Check for care gaps, Rx refills, vaccinations, recent test results



Provider / Physician

Confirm/document relevant diagnoses, confirm orders (Rx, labs)



Check Out Desk

Verify Rx refills & final questions

IF specialist office:
refer patient back to PCP for continuity of care

56

5 THINGS YOU CAN DO TODAY TO ELEVATE OFFICE PERFORMANCE IN VBC



Maintain your panel by reaching out to patients on your attribution report that have not been to the office this past year

Review your ED report and consider referring these patients to Care Management

Engage your billing vendor to verify they are using current and correct codes with claims

Order 3-month supplies of *eligible* maintenance medications to reduce costs and aid adherence

Ask patients to write an online review for your office/provider



57

MHN WEBSITE



[Find a Provider](#) [About Us](#) [Leadership](#) [Contact Us](#) [Privacy Policy](#)

The Leader in Value-Based Care

Provider Resources Review HEDIS 89 phrase, guidelines, and more. Click Here	Patient Outreach Materials Provide guidelines and educational materials to your patients. Click Here Click Here for Spanish	Coding Resources Stay current with value-based care documentation requirements. Click Here
Citizenship Metrics Materials Access links to the annual citizenship education metrics and topics. Click Here	Epic Resources Access Epic utilization details for your practice. Click Here	Find a Provider Search our directory to find a provider in the network. Click Here
FAQs Use this quick guide for answers to common questions. Click Here	Update Your Information Complete an online form to update your contact information in our directory. Click Here	



58

Questions?



Maria Castano, PharmD
MaCastano@mhs.net

